MA35725B1 - Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btk - Google Patents
Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btkInfo
- Publication number
- MA35725B1 MA35725B1 MA37107A MA37107A MA35725B1 MA 35725 B1 MA35725 B1 MA 35725B1 MA 37107 A MA37107 A MA 37107A MA 37107 A MA37107 A MA 37107A MA 35725 B1 MA35725 B1 MA 35725B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- compounds
- piperazine compounds
- btk activity
- alkylated piperazine
- Prior art date
Links
- 150000004885 piperazines Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne des composés pipérazines alkylés de la formule i, comprenant des stéréo-isomères, des tautomères et des sels de qualité pharmaceutique de ceux-ci, lesdits composés étant utiles pour l'inhibition de la kinase btk et pour le traitement de troubles immunitaires, tels qu'une inflammation à médiation par la kinase btk. L'invention concerne également des procédés d'utilisation des composés de la formule i pour un diagnostic
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161555395P | 2011-11-03 | 2011-11-03 | |
PCT/US2012/063198 WO2013067277A1 (fr) | 2011-11-03 | 2012-11-02 | Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btk |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35725B1 true MA35725B1 (fr) | 2014-12-01 |
Family
ID=47146780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37107A MA35725B1 (fr) | 2011-11-03 | 2014-06-06 | Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btk |
Country Status (22)
Country | Link |
---|---|
US (3) | US8729072B2 (fr) |
EP (1) | EP2773639B1 (fr) |
JP (2) | JP5976828B2 (fr) |
KR (1) | KR101716011B1 (fr) |
CN (1) | CN104024255B (fr) |
AR (1) | AR088642A1 (fr) |
AU (1) | AU2012332368A1 (fr) |
BR (1) | BR112014010439A2 (fr) |
CA (1) | CA2853970A1 (fr) |
CL (1) | CL2014001158A1 (fr) |
CO (1) | CO6950475A2 (fr) |
CR (1) | CR20140187A (fr) |
EA (1) | EA027561B1 (fr) |
IL (1) | IL232280A0 (fr) |
IN (1) | IN2014CN03265A (fr) |
MA (1) | MA35725B1 (fr) |
MX (1) | MX2014005289A (fr) |
PE (1) | PE20141686A1 (fr) |
SG (1) | SG11201401993RA (fr) |
TW (1) | TW201326171A (fr) |
WO (1) | WO2013067277A1 (fr) |
ZA (1) | ZA201403158B (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013021374A2 (fr) | 2011-08-05 | 2013-02-14 | Mitraltech Ltd. | Techniques pour le remplacement et la fixation percutanés d'une valvule mitrale |
UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
WO2013067277A1 (fr) * | 2011-11-03 | 2013-05-10 | Genentech, Inc. | Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btk |
CN105358545A (zh) | 2013-07-03 | 2016-02-24 | 豪夫迈·罗氏有限公司 | 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物 |
WO2015082583A1 (fr) | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Composés de pyridone hétéroarylique et d'aza-pyridone à fonctionnalité électrophile |
AU2014361800B2 (en) | 2013-12-13 | 2020-05-07 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
WO2015089479A1 (fr) | 2013-12-13 | 2015-06-18 | Dana-Farber Cancer Institute, Inc. | Procédé pour traiter un lymphome lymphoplasmocytaire |
WO2015151006A1 (fr) | 2014-03-29 | 2015-10-08 | Lupin Limited | Composés de purine substitués en tant qu'inhibiteurs de btk |
CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
WO2015170266A1 (fr) | 2014-05-07 | 2015-11-12 | Lupin Limited | Composés pyrimidine substitués en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk) |
JP6507234B2 (ja) * | 2014-10-02 | 2019-04-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ブルトンチロシンキナーゼ(btk)によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物 |
CA2965178C (fr) | 2014-10-22 | 2023-09-26 | Dana-Farber Cancer Institute, Inc. | Composes contenant des groupes thiazolyle pour le traitement de maladies proliferatives |
CN107108604B (zh) | 2014-10-27 | 2020-07-24 | 豪夫迈·罗氏有限公司 | 制备三环内酰胺化合物的方法 |
CN105837576B (zh) | 2015-01-14 | 2019-03-26 | 湖北生物医药产业技术研究院有限公司 | Btk抑制剂 |
CN114044760A (zh) * | 2015-03-10 | 2022-02-15 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物 |
CA2997859C (fr) | 2016-02-29 | 2024-06-04 | F. Hoffmann-La Roche Ag | Compositions de formes galeniques comprenant un inhibiteur de la tyrosine kinase de bruton |
MX2019006288A (es) | 2016-12-03 | 2020-10-01 | Juno Therapeutics Inc | Metodos y composiciones para el uso de celulas t terapeuticas en combinacion con inhibidores de quinasa. |
HRP20211553T1 (hr) * | 2016-12-15 | 2021-12-24 | F. Hoffmann - La Roche Ag | Postupak za pripravu inhibitora btk |
CN107445981B (zh) * | 2017-08-25 | 2018-06-22 | 牡丹江医学院 | 一种用于防治宫颈炎的活性化合物 |
CN113939292A (zh) | 2019-02-25 | 2022-01-14 | 广州麓鹏制药有限公司 | Btk及其突变体的抑制剂 |
MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
WO2021066958A1 (fr) | 2019-10-05 | 2021-04-08 | Newave Pharmaceutical Inc. | Inhibiteurs de btk et leurs mutants |
KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
IL295589A (en) | 2020-02-20 | 2022-10-01 | Hutchison Medipharma Ltd | The heterocyclic heteroaryl compounds and their uses |
CN115715291A (zh) * | 2020-06-18 | 2023-02-24 | 上海华汇拓医药科技有限公司 | 布鲁顿酪氨酸激酶抑制剂及其制备方法 |
CN116568687A (zh) | 2020-09-21 | 2023-08-08 | 和记黄埔医药(上海)有限公司 | 杂芳基杂环化合物及其用途 |
US20230382900A1 (en) | 2020-10-30 | 2023-11-30 | Newave Pharmaceutical Inc. | Inhibitors of btk |
US20240058457A1 (en) | 2020-12-20 | 2024-02-22 | Newave Pharmaceutical Inc. | Btk degrader |
WO2023143491A1 (fr) * | 2022-01-28 | 2023-08-03 | 和记黄埔医药(上海)有限公司 | Procédé de synthèse d'un composé 7,8-dihydro-2h-cyclopentapyrrolopyrazinone |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
BR0211073A (pt) | 2001-07-12 | 2004-12-14 | Avecia Ltd | Sistema de catalisador, e, processos para a preparação de um catalisador microencapsulado, de bifenilas opcionalmente substituìdas, de alcenos opcionalmente substituìdos, de um produto hidrogenado e de dióis |
WO2005014599A1 (fr) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines et methodes d'inhibition de la tyrosine kinase de bruton par de tels composes |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
CA2587192A1 (fr) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Certaines imidazo[1,2-a] pyrazin-8-ylamines et les procedes de fabrication et d'utilisation correspondants |
JP2008533032A (ja) | 2005-03-10 | 2008-08-21 | シージーアイ ファーマシューティカルズ,インコーポレイティド | 或る種の置換アミド、その製造方法及び使用方法 |
EP1934174B1 (fr) | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives |
AR063946A1 (es) | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
US7838523B2 (en) | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
PE20080839A1 (es) | 2006-09-11 | 2008-08-23 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
US8426441B2 (en) | 2007-12-14 | 2013-04-23 | Roche Palo Alto Llc | Inhibitors of bruton's tyrosine kinase |
US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
US8426424B2 (en) | 2008-05-06 | 2013-04-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
CN103408533B (zh) | 2008-06-24 | 2015-08-26 | 霍夫曼-拉罗奇有限公司 | 新型取代的吡啶-2-酮和哒嗪-3-酮 |
CA2728683C (fr) * | 2008-07-02 | 2017-05-02 | F.Hoffmann-La Roche Ag | Nouvelles phenylpyrazinones en tant qu'inhibiteurs de kinases |
WO2010006947A1 (fr) | 2008-07-15 | 2010-01-21 | F. Hoffmann-La Roche Ag | Nouvelles phényl-imidazopyridines et pyridazines |
US8598174B2 (en) | 2008-11-12 | 2013-12-03 | Genetech, Inc. | Pyridazinones, method of making, and method of use thereof |
US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
CA2748414A1 (fr) * | 2009-04-24 | 2010-10-28 | F. Hoffmann-La Roche Ag | Inhibiteurs de la tyrosine kinase de bruton |
JP5656976B2 (ja) * | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
CA3082212C (fr) * | 2009-09-04 | 2023-03-07 | Sunesis Pharmaceuticals, Inc. | Inhibiteurs de tyrosine kinase de bruton |
JP5832524B2 (ja) * | 2010-05-07 | 2015-12-16 | ジーアイリード コネチカット インコーポレーテッドGilead Connecticut,Inc. | ピリドン及びアザピリドン化合物、並びにそれらの使用方法 |
AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
CA2809836C (fr) * | 2010-09-01 | 2019-01-15 | Gilead Connecticut, Inc. | Pyridinones/pyrazinones, methodes de fabrication, et methode d'utilisation associee pour le traitement de troubles medies par la tyrosine kinase de bruton |
WO2012030990A1 (fr) | 2010-09-01 | 2012-03-08 | Gilead Connecticut, Inc. | Pyridazinones, leur procédé de fabrication et leur procédé d'utilisation |
JP5859640B2 (ja) | 2011-05-17 | 2016-02-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ブルトンチロシンキナーゼ阻害剤 |
AU2012296888A1 (en) | 2011-08-17 | 2014-01-23 | F. Hoffmann-La Roche Ag | Inhibitors of Bruton's Tyrosine Kinase |
WO2013067277A1 (fr) * | 2011-11-03 | 2013-05-10 | Genentech, Inc. | Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btk |
UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
-
2012
- 2012-11-02 WO PCT/US2012/063198 patent/WO2013067277A1/fr active Application Filing
- 2012-11-02 IN IN3265CHN2014 patent/IN2014CN03265A/en unknown
- 2012-11-02 EP EP12783838.1A patent/EP2773639B1/fr not_active Not-in-force
- 2012-11-02 JP JP2014541115A patent/JP5976828B2/ja not_active Expired - Fee Related
- 2012-11-02 PE PE2014000639A patent/PE20141686A1/es not_active Application Discontinuation
- 2012-11-02 MX MX2014005289A patent/MX2014005289A/es active IP Right Grant
- 2012-11-02 TW TW101140859A patent/TW201326171A/zh unknown
- 2012-11-02 US US13/667,114 patent/US8729072B2/en active Active
- 2012-11-02 SG SG11201401993RA patent/SG11201401993RA/en unknown
- 2012-11-02 CN CN201280065838.8A patent/CN104024255B/zh not_active Expired - Fee Related
- 2012-11-02 AU AU2012332368A patent/AU2012332368A1/en not_active Abandoned
- 2012-11-02 AR ARP120104129A patent/AR088642A1/es unknown
- 2012-11-02 KR KR1020147014782A patent/KR101716011B1/ko active IP Right Grant
- 2012-11-02 EA EA201490859A patent/EA027561B1/ru not_active IP Right Cessation
- 2012-11-02 BR BR112014010439A patent/BR112014010439A2/pt not_active Application Discontinuation
- 2012-11-02 CA CA2853970A patent/CA2853970A1/fr not_active Abandoned
-
2014
- 2014-04-07 US US14/246,471 patent/US8946213B2/en active Active
- 2014-04-24 CR CR20140187A patent/CR20140187A/es unknown
- 2014-04-28 IL IL232280A patent/IL232280A0/en unknown
- 2014-04-30 ZA ZA2014/03158A patent/ZA201403158B/en unknown
- 2014-04-30 CO CO14093206A patent/CO6950475A2/es active IP Right Grant
- 2014-05-02 CL CL2014001158A patent/CL2014001158A1/es unknown
- 2014-06-06 MA MA37107A patent/MA35725B1/fr unknown
- 2014-12-11 US US14/566,920 patent/US9115152B2/en active Active
-
2015
- 2015-08-24 JP JP2015165095A patent/JP2016028045A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20140221365A1 (en) | 2014-08-07 |
IN2014CN03265A (fr) | 2015-07-03 |
IL232280A0 (en) | 2014-06-30 |
SG11201401993RA (en) | 2014-05-29 |
US20150094302A1 (en) | 2015-04-02 |
TW201326171A (zh) | 2013-07-01 |
CN104024255A (zh) | 2014-09-03 |
EA027561B1 (ru) | 2017-08-31 |
CN104024255B (zh) | 2017-01-18 |
KR101716011B1 (ko) | 2017-03-13 |
PE20141686A1 (es) | 2014-11-08 |
CR20140187A (es) | 2014-06-20 |
AR088642A1 (es) | 2014-06-25 |
US8946213B2 (en) | 2015-02-03 |
EP2773639A1 (fr) | 2014-09-10 |
AU2012332368A1 (en) | 2014-05-22 |
WO2013067277A1 (fr) | 2013-05-10 |
JP5976828B2 (ja) | 2016-08-24 |
US20130116245A1 (en) | 2013-05-09 |
US8729072B2 (en) | 2014-05-20 |
JP2016028045A (ja) | 2016-02-25 |
JP2014532763A (ja) | 2014-12-08 |
CO6950475A2 (es) | 2014-05-20 |
MX2014005289A (es) | 2014-05-30 |
EP2773639B1 (fr) | 2017-04-26 |
KR20140090227A (ko) | 2014-07-16 |
BR112014010439A2 (pt) | 2017-04-18 |
CL2014001158A1 (es) | 2014-09-12 |
EA201490859A1 (ru) | 2014-09-30 |
CA2853970A1 (fr) | 2013-05-10 |
US9115152B2 (en) | 2015-08-25 |
ZA201403158B (en) | 2017-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35725B1 (fr) | Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btk | |
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
MA38398A1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
TN2015000347A1 (fr) | Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles | |
MA37439A1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
MD3411411T2 (ro) | Derivați de 1H-indazol-3-carboxamidă și compuși înrudiți în calitate de inhibitori ai factorului D pentru tratamentul bolilor caracterizate prin activitate aberantă a sistemului complementului, cum ar fi, de exemplu, tulburări imunologice | |
MA40123A1 (fr) | Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia | |
MA37142A3 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
MA35643B1 (fr) | Inhibiteur de cetp d'oxazolidinone bicyclique condensée | |
MA35348B1 (fr) | 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk | |
MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
MA34963B1 (fr) | Derives de fluoro-pyridinone utiles en tant qu'agents antibacteriens | |
MA37929B1 (fr) | Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch | |
MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
MA34234B1 (fr) | Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation | |
TN2013000393A1 (fr) | Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase | |
EA201492170A1 (ru) | Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ | |
MA37831B1 (fr) | Dérivés d'azaindole agissant comme inhibiteur de pi3k | |
MA38810B1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
EA201991916A1 (ru) | 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ | |
PH12020550168A1 (en) | Griseofulvin compound and pharmaceutical use thereof | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine |